Literature DB >> 3348943

Phase II evaluation of mitozolomide in ovarian cancer.

M Harding1, D Northcott, J Smyth, N S Stuart, J A Green, E Newlands.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3348943      PMCID： PMC2246691          DOI： 10.1038/bjc.1988.21

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

Review 1.  Common epithelial cancer of the ovary (2).

Authors:  G S Richardson; R E Scully; N Nikrui; J H Nelson
Journal:  N Engl J Med       Date:  1985-02-21       Impact factor: 91.245

2.  Phase I clinical trial of mitozolomide.

Authors:  E S Newlands; G Blackledge; J A Slack; C Goddard; C J Brindley; L Holden; M F Stevens
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

3.  Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.

Authors:  M F Stevens; J A Hickman; R Stone; N W Gibson; G U Baig; E Lunt; C G Newton
Journal:  J Med Chem       Date:  1984-02       Impact factor: 7.446

4.  Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.

Authors:  J A Hickman; M F Stevens; N W Gibson; S P Langdon; C Fizames; F Lavelle; G Atassi; E Lunt; R M Tilson
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

5.  Mitozolomide activity on human cancer cells in vitro.

Authors:  E Erba; S Pepe; P Ubezio; A Lorico; L Morasca; C Mangioni; F Landoni; M D'Incalci
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640
  5 in total
  4 in total

1.  Relationship between the pharmacokinetics and toxicity of mitozolomide.

Authors:  D J Kerr; J A Slack; P Secrett; M F Stevens; G R Blackledge; C Bradley; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.

Authors:  M McKeage; P Dady; M Clear; A MacDonald
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Authors:  E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

Review 4.  Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.

Authors:  Hannah Strobel; Tim Baisch; Rahel Fitzel; Katharina Schilberg; Markus D Siegelin; Georg Karpel-Massler; Klaus-Michael Debatin; Mike-Andrew Westhoff
Journal:  Biomedicines       Date:  2019-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.